Repronex 75 Iu Generic Name & Formulations
Follicle-stimulating hormone 75 IU + luteinizing hormone 75 IU; per vial; pwd for SC or IM inj after reconstitution.
Repronex 75 Iu Indications
Multiple follicular development for in vitro fertilization and ovulation induction in women who have previously received pituitary suppression.
Repronex 75 Iu Dosage and Administration
For controlled ovarian hyperstimulation: 150 IU daily for 1st 5 days of treatment, followed by 5000–10000 Units of hCG 1 day after last dose. ART: Initially 225 IU followed by 5000–10000 Units of hCG. For both: Adjust in increments of 75–150 IU at intervals of at least 2 days; max 450 IU/day and 12 days treatment.
Repronex 75 Iu Contraindications
Primary ovarian failure. Uncontrolled thyroid or adrenal dysfunction. Intracranial lesions. Undiagnosed abnormal vaginal bleeding. Ovarian cysts or enlargement. Pregnancy (Cat.X).
Repronex 75 Iu Boxed Warnings
Repronex 75 Iu Warnings/Precautions
Be fully familiar with infertility treatment and its complications before using this product. Do complete gynecological and endocrinological exam first. Monitor appropriate lab values. May cause false (+) pregnancy test. Thromboembolic disorders. If ovaries are excessively enlarged on last day of therapy do not administer hCG; this decreases risk of ovarian hyperstimulation syndrome (OHSS). Discontinue if OHSS occurs. Nursing mothers.
Repronex 75 Iu Pharmacokinetics
Repronex 75 Iu Interactions
Repronex 75 Iu Adverse Reactions
OHSS with pulmonary and vascular complications, hemoperitoneum, adnexal torsion, ovarian enlargement or cysts, abdominal pain, flu-like symptoms, GI disturbances, local reactions, rash, dizziness, tachycardia, dyspnea, tachypnea, risk of high order multiple births.
Repronex 75 Iu Clinical Trials
Repronex 75 Iu Note
Repronex 75 Iu Patient Counseling